Century Therapeutics (NASDAQ:IPSC) Insider Sells $25,693.80 in Stock

Century Therapeutics, Inc. (NASDAQ:IPSC) insider Gregory Russotti sold 10,076 shares of the business’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $2.55, for a total transaction of $25,693.80. Following the completion of the transaction, the insider owned 515,427 shares in the company, valued at $1,314,338.85. This represents a 1.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Gregory Russotti also recently made the following trade(s):

• On Monday, March 9th, Gregory Russotti sold 479 shares of Century Therapeutics stock. The stock was sold at an average price of $2.54, for a total value of $1,216.66.

Century Therapeutics Stock Performance

Shares of NASDAQ:IPSC traded up $0.09 during trading on Monday, hitting $2.43. The company’s stock had a trading volume of 815,753 shares, compared to its average volume of 1,847,081. The company has a market capitalization of $212.39 million, a PE ratio of -17.36 and a beta of 1.70. Century Therapeutics, Inc. has a fifty-two week low of $0.34 and a fifty-two week high of $3.04. The stock’s 50-day moving average price is $2.08 and its two-hundred day moving average price is $1.12.

Century Therapeutics (NASDAQ:IPSC) last issued its earnings results on Thursday, March 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. On average, equities analysts predict that Century Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Leerink Partners set a $2.00 price target on shares of Century Therapeutics and gave the company a “market perform” rating in a report on Friday. Zacks Research lowered shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Wall Street Zen upgraded shares of Century Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Piper Sandler lifted their price target on Century Therapeutics from $2.00 to $4.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Finally, TD Cowen initiated coverage on Century Therapeutics in a report on Wednesday, February 25th. They issued a “buy” rating for the company. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Century Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $3.80.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Adage Capital Partners GP L.L.C. bought a new position in Century Therapeutics during the 4th quarter valued at $1,829,000. Spruce Street Capital LP bought a new stake in Century Therapeutics in the fourth quarter worth about $1,414,000. Jane Street Group LLC acquired a new stake in Century Therapeutics in the 2nd quarter valued at about $248,000. Two Sigma Investments LP boosted its position in shares of Century Therapeutics by 59.2% during the 3rd quarter. Two Sigma Investments LP now owns 911,446 shares of the company’s stock valued at $454,000 after purchasing an additional 338,902 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its position in shares of Century Therapeutics by 483.1% during the 3rd quarter. Squarepoint Ops LLC now owns 236,053 shares of the company’s stock valued at $118,000 after purchasing an additional 195,573 shares in the last quarter. Institutional investors and hedge funds own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.